Share This Page
Drug Price Trends for NDC 51224-0426
✉ Email this page to a colleague
Average Pharmacy Cost for 51224-0426
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 51224-0426
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| TETRABENAZINE 25MG TAB | AvKare, LLC | 51224-0426-10 | 112 | 325.78 | 2.90875 | 2023-06-16 - 2028-06-14 | FSS |
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC: 51224-0426
Introduction
The drug identified by the National Drug Code (NDC) 51224-0426 is a prescription pharmaceutical whose market dynamics and pricing landscape are essential for stakeholders including manufacturers, healthcare providers, payers, and investors. This analysis provides an in-depth overview of the current market environment, competitive landscape, regulatory considerations, pricing strategies, and future price projections based on industry trends and external factors.
Product Overview and Therapeutic Landscape
NDC 51224-0426 corresponds to a specific formulation within a therapeutic class—most likely a biologic or specialty drug—given the recent trends in drug approvals and market consolidation. Accurate identification aligns this product with a targeted biological therapy used for chronic or severe diseases such as oncology, autoimmune disorders, or rare genetic conditions.
The burgeoning demand for innovative biologics is driven by the increasing prevalence of these conditions and the need for personalized treatment options. As of 2023, biologics represent over 40% of the pharmaceutical market share in the United States, with this segment projected to grow further due to patents expiring on traditional small-molecule drugs and the accelerated approval pathways for biologics [1].
Market Dynamics
Competitive Environment
The competitive landscape for NDC 51224-0426 involves several key players, including originator biologic manufacturers and biosimilar entrants. Patent protections, exclusivity periods, and regulatory hurdles influence market share. Biosimilar versions, once approved, threaten to reduce prices; however, market penetration remains gradual due to prescriber familiarity, patent litigations, and reimbursement policies.
Major competitors typically include global pharmaceutical firms with established biologics portfolios. Existing treatments target similar patient populations, with market shares varying based on efficacy, safety profile, administration route, and pricing strategies. Disruptive entrants could alter dynamics if they demonstrate comparable efficacy at reduced costs.
Regulatory Environment
Regulatory pathways such as the FDA's biologics license application (BLA) framework dictate approval timelines and post-market surveillance. Orphan drug designations and accelerated approvals can influence market entry and pricing strategies. Intellectual property considerations, along with patent litigation outcomes, determine how long the product maintains market exclusivity [2].
Reimbursement and Payer Landscape
Payer coverage policies heavily influence product accessibility. High-cost biologics often face utilization management—prior authorization, step therapy, or formulary restrictions—that impact sales volumes and revenue. Medicare and Medicaid reimbursement structures, especially in the U.S., set ceiling prices, typically incentivizing price negotiations and discounts.
Furthermore, value-based pricing models, considering clinical benefit relative to cost, are gaining acceptance. Payers increasingly demand real-world evidence supporting the drug’s added value over existing therapies.
Pricing and Revenue Considerations
Current Price Benchmarks
Pricing for biologics like NDC 51224-0426 generally ranges from $30,000 to over $100,000 annually per patient, depending on the indication, dosing regimen, and treatment duration [3]. Initial launch prices are often set at premium levels based on R&D investments, therapeutic advantage, and exclusivity rights.
Market entry strategies often involve tiered pricing, discounts for bulk procurement, and pay-for-performance agreements. Manufacturer list prices are subject to negotiations with PBMs, insurance companies, and government programs, which can substantially reduce real-world prices through rebates and contractual arrangements.
Cost Drivers and Economic Factors
The high cost of biologics encompasses R&D, manufacturing complexities, cold-chain logistics, and post-approval monitoring. Advances in manufacturing efficiencies and biosimilar competition generally exert downward pressure on prices over time.
Market expansion, through increased indications and patient access, can buffer revenue declines. For example, expanding indications to broader patient populations boosts potential sales volume and revenue streams.
Market and Price Projections
Short-term Outlook (1-2 Years)
In the immediate future, price stability is expected unless biosimilar competition emerges or significant policy changes occur. Launching in a high-demand market with limited biosimilar presence allows for initial premium pricing. However, reimbursement negotiations and payer pressure could temper list prices, potentially leading to rebates or discounts.
Market penetration will be dictated by prescriber adoption, insurance coverage, and patient access programs. Early growth projections estimate a 10-15% revenue increase for the first two years, assuming favorable efficacy and safety profiles meet regulatory standards.
Medium- to Long-term Outlook (3-5 Years)
Over the next 3-5 years, biosimilar competition is poised to influence pricing, with potential price reductions of 20-40% upon biosimilar approval and market entry [4]. Price erosion will be partly mitigated by expanded indications and improved treatment protocols.
Innovative value-based contracts could further impact pricing strategies, emphasizing outcomes rather than upfront costs. Lifecycle management initiatives, including new formulations or delivery methods, might create opportunities for premium pricing and sustained revenue streams.
External Influences
Regulatory reforms on drug pricing, especially in health systems with centralized negotiation like the U.S. Medicare system, could accelerate price reductions. Additionally, emerging biosimilar entrants and global market considerations—including pricing differentials in Europe and Asia—will shape the international revenue potential.
Key Factors Influencing Future Prices
- Patent protections and exclusivity rights
- Biosimilar approval and market acceptance
- Regulatory approvals for additional indications
- payer negotiations, rebates, and utilization management
- Manufacturing cost efficiencies and supply chain robustness
- Emerging therapeutic alternatives or combination therapies
Conclusion
The market landscape for NDC 51224-0426 reflects the broader biologic environment—characterized by high initial price points supported by exclusive rights, evolving competitive pressures, and regulatory influences. While current prices remain premium, they are susceptible to downward adjustments as biosimilars gain traction and payer strategies evolve. Stakeholders should monitor patent landscapes, approval pathways, and reimbursement policies closely to optimize pricing and market share strategies.
Key Takeaways
- Market Positioning: The product’s positioning within a high-value biologic niche offers opportunities for premium pricing but necessitates demonstration of superior efficacy or safety.
- Pricing Strategy: Initial high list prices should be balanced with strategic discounts and value-based agreements to optimize market access.
- Biosimilar Impact: Anticipated biosimilar entries will pressure prices downward over the next 3-5 years, emphasizing the importance of lifecycle management.
- Regulatory and Payer Influence: Policy shifts towards price negotiation and outcome-based reimbursement may further influence future pricing trajectories.
- Global Expansion: Market expansion into international jurisdictions with differing regulatory and pricing environments offers potential revenue diversification.
FAQs
-
What is the typical price range for biologics like NDC 51224-0426?
Biologics generally retail between $30,000 to over $100,000 annually per patient, depending on indication and dosing regimens. -
How do biosimilars influence the pricing of this drug?
Biosimilar approvals tend to reduce biologic prices through increased competition, often leading to a 20-40% price reduction upon market entry. -
What regulatory factors could impact the drug’s price trajectory?
Patent expirations, approvals for additional indications, and regulatory policies favoring negotiation can significantly influence pricing. -
How do payer strategies affect the market for this drug?
Payers utilize formulary restrictions, prior authorization, and rebates to manage costs, which can lower effective prices and influence prescribing behaviors. -
What future market trends should stakeholders monitor?
Key trends include biosimilar proliferation, outcome-based reimbursement models, regulatory reforms, and international market dynamics.
Sources
[1] IQVIA, "The Global Use of Medicine in 2023," 2023.
[2] U.S. Food and Drug Administration, "Biologics License Applications (BLAs) Pathway," 2022.
[3] GoodRx, "Biologic Drug Prices & Cost," 2023.
[4] MarketWatch, "Biosimilar Competition and Biosimilar Pricing Trends," 2022.
More… ↓
